Faculty, Staff and Student Publications
Publication Date
9-1-2024
Journal
Chinese Medical Journal Pulmonary and Critical Care Medicine
Abstract
Targeted therapy has ushered in a new era of precision medicine for non-small cell lung cancer (NSCLC). Currently, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) stand as the recommended first-line therapy for advanced NSCLC harboring sensitive EGFR mutations. Nevertheless, most patients inevitably confront the challenge of drug resistance. This phenomenon arises not solely from intrinsic alterations within cancer cells but also from the intricate dynamics of the tumor microenvironment and the complex interactions that occur between cancer cells and their immediate surroundings. This review consolidates the current knowledge regarding EGFR-TKI resistance mechanisms, with a specific emphasis on unraveling the role played by the tumor microenvironment. In addition, the review delineates strategic approaches to surmount TKI resistance, thereby enriching the understanding of the interplay between therapeutic agents and the intricate milieu surrounding cancer cells.
Keywords
Non-small cell lung cancer, Epidermal growth factor receptor, Tumor microenvironment, Epidermal growth factor receptor-tyrosine kinase inhibitor, Drug resistance
DOI
10.1016/j.pccm.2024.08.002
PMID
39403414
PMCID
PMC11471126
PubMedCentral® Posted Date
9-16-2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Critical Care Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons, Pulmonology Commons